Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
7 papers
Recent·Most cited
N. B. Fernandez, S. M. Sosa, J. T. Roberts…·N. Rubinstein
This study shows that RUNX1 is regulated by androgen receptor in TNBC, promoting cancer stem cell markers and chemotherapy resistance.
K. I. O'Neill, L.-W. Kuo, M. M. Williams…·J. K. Richer
This study identifies NPC1 as a key driver of metabolic flexibility and aggressiveness in TNBC, showing its role in cholesterol homeostasis and therapeutic vulnerability.
Z. Li, Y. Wu, M. E. Yates…·S. Oesterreich
This study identifies ESR1 mutations as drivers of breast cancer metastasis by altering cell adhesion and migration through genomic and transcriptomic reprogramming.
Z. Li, Y. Wu, A. Bahreini…·S. Oesterreich
This study shows ESR1 mutant breast cancers exhibit basal cytokeratin expression and immune activation, linked to chromatin reprogramming and paracrine signaling.
K. R. Jordan, M. J. Sikora, J. E. Slansky…·B. G. Bitler
This study identifies an IL-6/IER3 inflammatory signaling axis linked to chemo-resistance in ovarian cancer by analyzing pre- and post-chemotherapy tumor microenvironment changes.
L. S. Crump, G. L. Wyatt, T. R. Rutherford…·T. R. Lyons
This study identifies SEMA7A as a driver of therapeutic resistance in ER+ breast cancer and suggests targeting survival signaling pathways as a potential treatment strategy.
S. Arnesen, Z. Blanchard, M. M. Williams…·J. Gertz
This study shows that ER mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects, not just ligand independence.